[go: up one dir, main page]

PE20040916A1 - PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13 - Google Patents

PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13

Info

Publication number
PE20040916A1
PE20040916A1 PE2003001280A PE2003001280A PE20040916A1 PE 20040916 A1 PE20040916 A1 PE 20040916A1 PE 2003001280 A PE2003001280 A PE 2003001280A PE 2003001280 A PE2003001280 A PE 2003001280A PE 20040916 A1 PE20040916 A1 PE 20040916A1
Authority
PE
Peru
Prior art keywords
alkyl
pyrimidin
halogen
substituted
mmp
Prior art date
Application number
PE2003001280A
Other languages
Spanish (es)
Inventor
Otmar Klingler
Reinhard Kirsch
Jorg Habermann
Klaus-Ulrich Weithmann
Christian Engel
Bernard Pirard
Original Assignee
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Gmbh filed Critical Aventis Pharma Gmbh
Publication of PE20040916A1 publication Critical patent/PE20040916A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A DIAMIDAS DE ACIDO PIRIMIDIN-4,6-DICARBOXILICO DE FORMULA I DONDE R1 ES H O ALQUILO C1-C6; R2 ES ALQUILO C1-C6 SUSTITUIDO UNA A TRES VECES POR C(O)-O-R8, ALQUIL(C1-C6)-O-R8, ENTRE OTROS; R3, R4, R5, R6 y R7 SON H, HALOGENO, ALQUILO C1-C6 NO SUSTITUIDO O SUSTITUIDO HASTA TRES VECES POR HALOGENO, O-ALQUILO C1-C6 NO SUSTITUIDO O SUSTITUIDO HASTA TRES VECES POR HALOGENO, S-ALQUILO C1-C6; R8 ES H O ALQUILO C1-C6. SON COMPUESTOS PREFERIDOS: [4-({[6-(4-FLUORO-3-METILBENCILCARBAMOIL)-PIRIMIDIN-4-CARBONIL]AMINO}METIL)FENOXI] ACETATO DE TERC-BUTILO; ACIDO [4-({[6-(4-FLUORO-3-METILBENCILCARBAMOIL)-PIRIMIDIN-4-CARBONIL]AMINO}METIL)FENOXI] ACETICO, ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA PREPARAR ESTOS COMPUESTOS Y UN PRODUCTO FARMACEUTICO. ESTOS COMPUESTOS SON UTILES PARA LA PROFILAXIS Y LA TERAPIA DE ENFERMEDADES CUYO CURSO IMPLICA UNA ACTIVIDAD INCREMENTADA DE METALOPROTEINASA DE MATRIZ 13 COMO SON ENFERMEDADES DEGENERATIVAS DE LAS ARTICULACIONES, ENFERMEDADES DEL TEJIDO CONECTIVO, ENFERMEDADES CANCEROSASREFERS TO DIAMIDES OF PYRIMIDIN-4,6-DICARBOXYLIC ACID OF FORMULA I WHERE R1 IS H OR C1-C6 ALKYL; R2 IS C1-C6 ALKYL SUBSTITUTED ONE TO THREE TIMES BY C (O) -O-R8, (C1-C6) -O-R8 ALKYL, AMONG OTHERS; R3, R4, R5, R6 and R7 ARE H, HALOGEN, C1-C6 ALKYL NOT REPLACED OR SUBSTITUTED UP TO THREE TIMES BY HALOGEN, OR C1-C6 ALKYL NOT REPLACED OR SUBSTITUTED UP TO THREE TIMES BY HALOGEN, S-C6 RENTAL ; R8 IS H OR C1-C6 ALKYL. PREFERRED COMPOUNDS ARE: [4 - ({[6- (4-FLUORO-3-METHYLBENZYLCARBAMOYL) -PYRIMIDIN-4-CARBONYL] AMINO} METHYL) PHENOXY] THIRD-BUTYL ACETATE; [4 - ({[6- (4-FLUORO-3-METHYLBENZYLCARBAMOIL) -PYRIMIDIN-4-CARBONYL] AMINO} METHYL) PHENOXY] ACETIC ACID, AMONG OTHERS. IT ALSO REFERS TO A PROCEDURE FOR PREPARING THESE COMPOUNDS AND A PHARMACEUTICAL PRODUCT. THESE COMPOUNDS ARE USEFUL FOR THE PROPHYLAXIS AND THERAPY OF DISEASES WHOSE COURSE INVOLVES AN INCREASED ACTIVITY OF MATRIX METALOPROTEINASE 13 AS THEY ARE DEGENERATIVE DISEASES OF THE JOINTS, DISEASES OF THE CONNECTED CANNER,

PE2003001280A 2003-01-03 2003-12-12 PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13 PE20040916A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10300017A DE10300017A1 (en) 2003-01-03 2003-01-03 Selective MMP 13 inhibitors

Publications (1)

Publication Number Publication Date
PE20040916A1 true PE20040916A1 (en) 2005-01-25

Family

ID=32519591

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003001280A PE20040916A1 (en) 2003-01-03 2003-12-12 PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13

Country Status (11)

Country Link
EP (1) EP1587803A1 (en)
JP (1) JP2006515595A (en)
AR (1) AR042687A1 (en)
AU (1) AU2003293951A1 (en)
BR (1) BR0317834A (en)
CA (1) CA2512183A1 (en)
DE (1) DE10300017A1 (en)
MX (1) MXPA05006401A (en)
PE (1) PE20040916A1 (en)
TW (1) TW200505906A (en)
WO (1) WO2004060883A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060173183A1 (en) * 2004-12-31 2006-08-03 Alantos Pharmaceuticals, Inc., Multicyclic bis-amide MMP inhibitors
US20070155737A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
US20070155738A1 (en) * 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
AU2006332694A1 (en) * 2005-12-30 2007-07-12 Alantos Pharmaceuticals, Holding, Inc. Substituted bis-amide metalloprotease inhibitors
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
WO2008063670A1 (en) * 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic matrix metalloprotease inhibitors
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN105130948A (en) 2010-04-22 2015-12-09 弗特克斯药品有限公司 Pharmaceutical compositions and administrations thereof
EP3424534B1 (en) 2014-04-15 2021-06-02 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
GB201908453D0 (en) * 2019-06-12 2019-07-24 Enterprise Therapeutics Ltd Compounds for treating respiratory disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3931432A1 (en) * 1989-09-21 1991-04-04 Hoechst Ag PYRIMIDIN-4,6-DICARBONSAEUREDIAMIDE, METHOD FOR THE PRODUCTION AND USE THEREOF AND MEDICINAL PRODUCTS BASED ON THESE COMPOUNDS
WO2002064571A1 (en) * 2001-02-14 2002-08-22 Warner-Lambert Company Llc Pyrimidine matrix metalloproteinase inhibitors
DE10160357A1 (en) * 2001-12-08 2003-06-18 Aventis Pharma Gmbh Use of pyridine-2,4-dicarboxylic acid diamides and pyrimidine-4,6-dicarboxylic acid diamides for the selective inhibition of collagenases

Also Published As

Publication number Publication date
AR042687A1 (en) 2005-06-29
WO2004060883A1 (en) 2004-07-22
EP1587803A1 (en) 2005-10-26
DE10300017A1 (en) 2004-07-15
CA2512183A1 (en) 2004-07-22
MXPA05006401A (en) 2005-08-19
AU2003293951A1 (en) 2004-07-29
TW200505906A (en) 2005-02-16
BR0317834A (en) 2005-11-29
JP2006515595A (en) 2006-06-01

Similar Documents

Publication Publication Date Title
SE0200979D0 (en) New compounds
BRPI0414867A (en) pyrazolopyridines and their analogues
SE9903760D0 (en) New compounds
MXPA04000905A (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them.
MXPA04007470A (en) Substituted pyridinones as modulators of p38 map kinase.
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
TW200517109A (en) Substituted pyridinones
EA200970611A1 (en) SUBSTITUTED PYRAZOLOHINAZYLINE DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS KINASE INHIBITORS
HRP20050967B1 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
NO20012158L (en) Substituted 2-phenylbenzimidazoles, process for preparation and use thereof
NO20093464L (en) New drug mixtures based on anti-cholinergically effective compounds and beta-mimetics
BRPI0408990A (en) pyrimidin-4-one derivatives and their use as p38 kinase modulators
WO2005016867A3 (en) Anthranilic acid derivatives and their use as activators of the hm74a receptor
NO990433L (en) New compounds and compositions for the treatment of diseases associated with tryptase activity
BRPI0413438A (en) active pyrimidylpyrrole derivatives as kinase inhibitors
PE20040916A1 (en) PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
WO2003063791A3 (en) Non-steroidal analogs of 2-methoxyestradiol
EE200200504A (en) Pharmaceutical preparations
DE60031686D1 (en) PYRAZINONE, COMPOSITIONS CONTAINING THESE COMPOUNDS
EA200401319A1 (en) NEW HETEROCYCLIC COMPOUNDS, METHODS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS AND THEIR USE IN MEDICINE
UY29823A1 (en) SUBSTITUTED DERIVATIVES OF 7-CHLORINE-3H-IMIDAZOL- (4,5-B) PIRIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PROCESSES FOR THE PREPARATION OF THE SAME AND APPLICATIONS
ATE444069T1 (en) QUINOLINE DERIVATIVES FOR THE TREATMENT OF MGLUR5 RECEPTOR-MEDIATED DISEASES
DE2963010D1 (en) 3-chloro-6-hydroxy-5-methylbenzoic acid derivatives, corresponding pharmaceutical preparations, growth promoting compositions, the use of the compounds for promoting growth in certain animals and their manufacture
MXPA05012369A (en) Benzothiazole derivatives and use thereof in the treatment of diseases relates to the adenosine a2a receptor.

Legal Events

Date Code Title Description
FC Refusal